Everything that could have gone wrong for oilfield services company Flotek Industries Inc. (NYSE: FTK) did so in the second quarter, according to Seaport Global.
Flotek's Q2 earnings fell short on both revenue and margins, and the company notably lost its largest customer, Urban said in a Wednesday downgrade note.
The company’s channels to U.S. markets are deteriorating, resulting in a 25-percent increase in net debt, the analyst said.
Despite management’s announcement of the largest CnF order in company history, revenue continues to fall well below estimates, Urban said.
Urban considers the quarter to be a big miss and outlined what he sees as risks for Flotek in the note:
- Demand for Flotek’s products is largely reliant on oil and natural gas expenditures, and the recent decline in these expenditures will likely halt growth and concern investors.
- Government regulations surrounding the production of resources could impair demand for Flotek’s services.
“Certain anti-takeover provisions in FTK’s charter documents and applicable Delaware law could discourage or prevent others from acquiring the company, adversely impacting its share price,” Urban said.
“Certain provisions include the ability to issue up to 100,000 shares of preferred stock, prohibit shareholders from calling special meetings, limit the ability of shareholders to act by written consent, prohibit cumulative voting and require advance notice for stockholder proposals and nominations for election to the board of directors to be acted upon at meetings of stockholders.”
Flotek shares were plunging 24.31 percent to $2.20 at the time of publication Wednesday.
Energy ETFs: A Credible Value Destination
Morgan Stanley Updates MLP Sector After FERC Decision
Latest Ratings for FTK
|Aug 2018||Seaport Global||Downgrades||Buy||Neutral|
|Jan 2016||Seaport Global||Upgrades||Accumulate||Strong Buy|
|Dec 2015||KLR Group||Initiates Coverage on||Buy|
View More Analyst Ratings for FTK
View the Latest Analyst Ratings
See more from Benzinga
- JPMorgan Downgrades Cimarex As Oil Growth Doubt Lingers
- Mizuho Upgrades Audentes On Promising Gene Therapy Candidate
- Jefferies: Snap's New CFO Is A Positive, Decline In User Growth A Concern
© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.